iBio, Inc.
Financial highlights
| Metric | FY 06/30/25 | FY 06/30/24 | FY 06/30/23 | FY 06/30/22 | FY 06/30/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $400,000 | $225,000 | $0 | $1.9M | $2.4M |
| Cost of revenue | — | — | — | $216,000 | $1.5M |
| Gross profit | — | — | — | $2.2M | $909,000 |
| Research and development | $8.3M | $5.2M | $10.3M | $9.8M | $10.0M |
| Operating expenses | $19.0M | $16.9M | $29.3M | $31.6M | $32.0M |
| Operating income | -$18.6M | -$16.6M | -$29.3M | -$29.7M | -$31.1M |
| Interest expense | $212,000 | $172,000 | $83,000 | $1.4M | $2.5M |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$18.4M | -$24.9M | -$65.0M | -$50.3M | -$23.2M |
| Balance Sheet | |||||
| Cash and equivalents | $8.6M | $14.2M | $4.3M | $22.7M | $77.4M |
| Current assets | $9.7M | $15.7M | $26.3M | $45.1M | $104.6M |
| Total assets | $23.2M | $28.7M | $41.2M | $99.4M | $147.0M |
| Current liabilities | $6.1M | $3.8M | $22.1M | $30.4M | $6.6M |
| Total liabilities | $8.3M | $7.4M | $25.8M | $35.9M | $38.4M |
| Stockholders' equity | $14.9M | $21.3M | $15.4M | $63.5M | $108.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$15.3M | -$18.6M | -$30.4M | -$37.5M | -$30.1M |
| Depreciation and amortization | $484,000 | $638,000 | $674,000 | $2.3M | $472,000 |
| Stock-based compensation | $1.5M | $2.0M | $4.4M | $4.4M | $1.6M |
| Capital expenditure | $16,000 | $210,000 | $5.7M | $7.3M | $4.9M |
| Free cash flow | -$15.3M | -$18.8M | -$36.2M | -$44.8M | -$35.0M |
| Impairments | — | $3.1M | $17.9M | — | — |
Shares outstanding 49.7M · Free float 42.3%
Annual filing data through FY ended June 30, 2025; float as of July 13, 2026.